Omipalisib
产品编号: DC7141
Featured
我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
Omipalisib (GSK2126458) 是一种高选择性，有效的 PI3K 抑制剂，抑制 p110α/β/δ/γ，mTORC1/2 的活性，Ki 值分别为 0.019 nM/0.13 nM/0.024 nM/0.06 nM 和 0.18 nM/0.3 nM。
| Cas No.: |
1086062-66-9 |
| 名称: |
2,4-difluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide |
| 别名: |
|
| SMILES: |
C(S(NC1=CC(C2=CC=C3C(=C2)C(C2=CC=NN=C2)=CC=N3)=CN=C1OC)(=O)=O)1=CC=C(F)C=C1F |
| 分子式: |
C25H17F2N5O3S |
| 分子量: |
505.5 |
| 纯度: |
|
| 保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
|
| In Vivo: |
|
| In Vitro: |
|
| References: |
GSK2126458 potently inhibits the activity of common activating mutants of p110α (E542K, E545K, and H1047R) found in human cancer with Ki of 8 pM, 8 pM and 9 pM, respectively. GSK2126458 causes a significant reduction in the levels of pAkt-S473 with remar |
| Kinase Assay: |
|
| Cell Assay: |
|
| Animal Administration: |
|
| References: |
|
MSDS
COA
| LOT NO. |
DOWNLOAD |
|
|
| 2018-0101 |
|
询盘
